RxDoctor Payments Data

Chad Ward, DO

Internal Medicine · Harrisburg, PANPI 1477841468

Payments from drug & device makers

$16,745in general payments, 2019–2025

Across 1,044 payments — averaging $16.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • Novo Nordisk$2K
  • Amgen$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • AbbVie$1K
  • plus $7K from 49 others

What the payments were for

  • Food & beverage$16,713100%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,745 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$187,216
Medicare patients
242
Services billed
2,800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban149$139,932
JardianceEmpagliflozin111$98,738
OzempicSemaglutide57$66,052
MounjaroTirzepatide51$62,051
FarxigaDapagliflozin Propanediol44$54,823
TrulicityDulaglutide49$48,140
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$30,441
XareltoRivaroxaban31$25,877
JanuviaSitagliptin Phosphate28$18,964
TradjentaLinagliptin16$11,829
Atorvastatin Calcium680$9,331
Dexlansoprazole DrDexlansoprazole15$6,022
Rosuvastatin Calcium246$5,640
Pitavastatin Calcium11$5,517
Tamsulosin Hcl265$5,379

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$962$139,932149 claims
Boehringer IngelheimJardiance, Tradjenta$1,079$110,568127 claims
Lilly USA, LLCMounjaro, Trulicity$1,215$110,191100 claims
Novo NordiskOzempic$2,044$66,05257 claims
AstraZenecaFarxiga$1,486$54,82344 claims
GSKTrelegy Ellipta$2,122$30,44146 claims
Johnson & JohnsonXarelto$679$25,87731 claims
MerckJanuvia$141$18,96428 claims
AbbVieViberzi, Synthroid$1,086$9,05688 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Harrisburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →